Ado-Trastuzumab Emtansine - A Medication For HER2-Positive Breast Cancer

Overview:

Trastuzumab emtansine, formerly known as Trastuzumab-DM1 (T-DM1), is a first-in-class HER2 antibody-drug conjugate (ADC) consisting of cell-killing chemical, DM1, and Trastuzumab antibody. T-DM1 induces cell cycle arrest and death by combining two methods: targeted intracellular administration of the powerful anti-microtubule drug, DM1 (a derivative of maytansine), and anti-HER2 action. Trastuzumab emtansine is prescribed for use in patients with HER2-positive metastatic breast cancer who have previously undergone taxane or Trastuzumab treatment for metastatic illness or whose cancer returned within six months of receiving adjuvant therapy. There are two warnings on the FDA label. First of all, Trastuzumab and emtansine are not interchangeable. Secondly, a black box warning about major adverse effects like cardiac, embryo-fetal, and hepatotoxic (toxic to liver) consequences is present.

Drug Group:

An antibody-drug conjugate (ADC), or combination of a monoclonal antibody and a small-molecule medication, is Trastuzumab emtansine. Every Trastuzumab emtansine molecule is made up of many cytotoxic maytansinoid (DM1) molecules coupled to a single Trastuzumab molecule. A heterobifunctional crosslinker, or SMCC (succinimide trans-4-(maleimidylmethyl) cyclohexane-1-carboxylate), is a kind of chemical reagent that has two reactive functional groups: a maleimide and a succinimide ester. The maleimide moiety of SMCC attaches itself to the free sulfhydryl group of DM1, creating a covalent binding between the antibody and the DM1, and the succinimide group of SMCC reacts with the free amino group of a lysine residue in the Trastuzumab molecule. By attaching to the plus ends of cellular microtubules, DM1 prevents the target tumor cells from proliferating.

Dosage Forms and Strengths:

Injection: powder that has been lyophilized for reconstitution.

• 100 mg (milligram) or 160 mg per vial.

• 20 mg/mL after reconstituted.

For Patients

What Is Trastuzumab Emtansine?

Trastuzumab emtansine is an antibody-drug conjugate that consists of the humanized monoclonal antibody Trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone inhibits the growth of cancer cells by binding to the HER2 receptor, while Trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released, and then binds tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) (Whereas hetero-dimerization can involve an interaction between two or more G protein-coupled receptors (GPCRs), homodimerization involves the interaction of two identical G protein-coupled receptors (GPCRs)) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signaling pathways.

A phase III clinical trial that compared Trastuzumab emtansine versus Capecitabine plus Lapatinib in 991 people with unresectable, locally advanced, or metastatic HER2-positive breast cancer who had previously been treated with Trastuzumab and Taxane chemotherapy provided the basis for Trastuzumab emtansine's approval in the United States, specifically for the treatment of HER2-positive metastatic breast cancer (mBC) in patients who had previously received treatment with Trastuzumab and a Taxane (Paclitaxel or Docetaxel).

What Dangerous Side Effects Of Ado-Trastuzumab Emtansine Likely To Cause?

Respiratory Issues:

Trastuzumab emtansine may result in lung issues, such as potentially fatal lung tissue inflammation. Indications of respiratory issues can include dyspnea, productive cough, fatigue, and pulmonary fluid accumulation.

Infusion Reactions:

An infusion-related response may manifest as one or more of the following symptoms: the flushing or heating of the skin, chills, fever, dyspnea, hypotension, wheezing, constriction of the chest muscles surrounding the airways, or rapid heartbeat. The physician will keep an eye out for any responses from the infusion.

Severe Bleeding:

Trastuzumab emtansine may result in fatal hemorrhage. The risk of bleeding may rise if one uses Trastuzumab emtansine with other drugs that thin the blood (antiplatelet) or prevent blood clots (anticoagulation). If one is using Trastuzumab emtansine and one of these other medications, the doctor should provide extra attention. Trastuzumab emtansine has the potential to cause life-threatening bleeding, even in the absence of blood thinners.

Low Level Of Platelets:

Low platelet counts can occur during Trastuzumab emtansine treatment. Platelets make blood clots easier. Prolonged bleeding from cuts, easy bruising, and bleeding are indicators of insufficient platelets. In minor instances, there could not be any signs.

Nerves Injury

A few possible symptoms are tingling and numbness, searing or acute pain, touch sensitivity, lack of coordination, weakening, or loss of muscle function. The physician will check one for signs of nerve injury.

Skin Responses Near the Site of Infusion:

Trastuzumab emtansine can leak from a vein or needle, which could result in adverse effects such as skin irritation, redness, soreness, discomfort, or swelling at the infusion site. If this occurs, it is more likely to do so 24 hours after the injection.

Which Adverse Effects of Trastuzumab Emtansine Are Most Frequently Reported?

When using Trastuzumab emtansine to treat early-stage breast cancer, the following are the most frequent side effects:

• Fatigue.

• Emesis.

• Liver issues.

• Pain affects the tendons, ligaments, muscles, and bones.

• Gushing blood.

• Low number of platelets.

• Headache.

• Hand and foot discomfort, numbness, and weakness.

• Joint discomfort.

When taking this medication for metastatic breast cancer, the following adverse effects are most frequently observed:

• Fatigue.

• Vomiting.

• Pain that is affecting the tendons, ligaments, muscles, and bones.

• Gushing blood.

• Low number of platelets.

• Headache.

• Liver issues.

• Bloating and nosebleeds.

For Doctors:

Indication:

It is utilized in patients with HER2-positive metastatic breast cancer who have previously had treatment for metastatic illness with Taxanes like Trastuzumab or whose cancer returned within six months of receiving adjuvant therapy.

Pharmacology:

Pharmacodynamics

Two Trastuzumab-responsive and one Trastuzumab-resistant breast tumor study models were used to assess Trastuzumab emtansine. Trastuzumab by itself decreased tumor growth in the Trastuzumab-responsive animals, while Trastuzumab-DM1 completely regressed tumors in every mouse. In the Trastuzumab resistance model, Trastuzumab did not inhibit tumor growth on its own. On the other hand, all animals treated with Trastuzumab-DM1 had tumor reductions of more than 90 percent. Tumor regrowth was shown in this Trastuzumab-resistant mouse following the stop of Trastuzumab-DM1 treatment; however, regression returned upon restarting the medication. The impact was unique to tumors that were HER2-positive. Trastuzumab emtansine hence causes cell cycle arrest and apoptosis-induced cell death as physiological effects.

Mechanism Of Action:

A conjugate of HER2 antibody and medication is Trastuzumab emtansine. Trastuzumab, a humanized anti-HER2 IgG1 generated in mammalian Chinese hamster ovary cells, is the antibody component. The medication DM1 is a derivative of maytansine that inhibits microtubules. 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), a stable thioether linker, covalently joins these two sections. Emtansine is the collective name for MCC and DM1, which are created through chemical synthesis.

By binding to the HER2 receptor's sub-domain IV, Trastuzumab emtansine enters cells through receptor-mediated endocytosis. Trastuzumab emtansine is broken down by lysosomes, releasing DM1. DM1 binds to tubulin in microtubules and inhibits microtubule function, inducing cell arrest and apoptosis. Moreover, in vitro research has demonstrated that Trastuzumab emtansine mediates both antibody-dependent cytotoxicity and the suppression of HER2 receptor signaling, just like Trastuzumab does.

• Volume Of Distribution: Trastuzumab emtansine has a distribution volume of roughly 3.13 L.

• Binding of Proteins: DM1 exhibits a 93 percent binding value to plasma proteins.

• Metabolism: Lysosomal degradation of trastuzumab emtansine results in MCC-DM1, Lys-MCC-DM1, and DM1. Low concentrations of each of these products are found in the plasma. DM1 undergoes further degradation by CYP3A4 and CYP3A5, but DM1 does not induce or inhibit any of the CYP450 enzymes.

• Route of Elimination: The route of elimination has not yet been fully elucidated.

• Half-life: Trastuzumab emtansine has a long half-life of about four days.

• Clearance After intravenous (IV) infusion, Trastuzumab emtansine has a clearance of 0.68 L/day.

• Toxicity: The FDA label includes a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

What Is Dose Consideration In Breast Cancer Patients?

Early Stages Breast Cancer:

• Recommended as a single treatment for HER2-positive early breast cancer (EBC) patients who have had neoadjuvant taxane and trastuzumab-based treatment but still have invasive disease.

• Three weeks at 3.6 mg/kg IV.

• Never provide a dose greater than 3.6 mg/kg.

• Treat the patient for a total of 14 cycles until the condition recurs or intolerable toxicity occurs.

Breast cancer with Metastases

• Recommended as a single treatment for HER2-positive metastatic breast cancer (MBC) in patients who have had trastuzumab and a taxane before, either separately or together, and who have either had therapy for metastatic disease in the past or experienced a recurrence of their disease during or within six months of finishing adjuvant therapy.

• Three weeks at 3.6 mg/kg IV.

• Never provide a dose greater than 3.6 mg/kg.

• Continue until the illness returns or the toxicity becomes intolerable.

Changes in Dosage

• Lower dosage in response to negative occurrences.

• Once the dose has been reduced, do not increase it again.

• Initial dosage decrease: 3 milligrams per kilogram.

• A second dosage decrease of 2.4 mg/kg.

• Need for additional dosage reduction: Stop taking the medication.

Selection of Patients

• Choose patients based on tumor specimens with overexpressed HER2 protein or amplified HER2 gene.

• Utilize FDA-approved tests designed specifically for breast malignancies to evaluate HER2 protein overexpression or HER2 gene amplification, carried out by facilities with proven expertise.

How Ado-Trastuzumab Emtansine Affects The Reproductive System?

Pregnancy And Lactation:

When given to a pregnant woman, pregnancy therapy can harm the fetus. No information is available on use in expectant mothers; instances of oligohydramnios and oligohydramnios sequence, which can cause skeletal deformities, pulmonary hypoplasia, and infant death, have been reported in postmarketing patient settings utilizing the antibody component Trastuzumab.

When given to a pregnant woman, the DM1 component may potentially harm the developing embryo. This is because of its mode of action. Inform the patient of possible hazards to a baby; if the drug is taken in a pregnant patient or if the patient becomes pregnant within seven months of the previous dose, clinical considerations must be made.

Possibility of Reproduction

Check the state of pregnancy in women who are capable of bearing children before starting treatment.

Contraception

If given to pregnant women, the drug may harm the developing fetus; thus, women who are capable of becoming pregnant should take adequate contraception during therapy and for seven months after the final dosage.

Male patients with female partners who may become pregnant should be advised to utilize effective contraception during therapy and for four months after the final dose due to the possibility of genotoxicity.

Unable to Conceive

Treatment may reduce fertility in both males and females who are capable of reproducing, according to findings from studies on the toxicity of animals. If the effects are reversible, it is unknown.

Lactation:

The cytotoxic component of the medication, diabetes mellitus (DM1), may cause serious adverse reactions in breastfed infants based on its mechanism of action; advise women not to breastfeed during treatment and for seven months after the last dose of the medication. There is no information available regarding the presence of ado-trastuzumab emtansine in human milk, its effects on breastfed infants, or milk production.

Pregnancy Categories:

• A: Acceptable in most cases. Pregnant women participating in controlled research do not exhibit any fetal risk.

• B: That could be fine. Either human research has not been conducted, and animal studies indicate no risk or animal studies have been conducted and reveal some risk but no harm overall.

• C: If the advantages outweigh the hazards, use caution. research on animals indicates risk, but there is no human research available.

• D: When there is no safer medication available, use it in life-threatening situations. Positive proof of prenatal danger in humans.

• X: Avoid using while expecting. The risks are greater than the possible rewards. There are safer options available.

• NA: No information is available.

Administration

Incompatibilities: With five percent dextrose IV. Avoid combining or using it as an infusion with other medications.

Suitability: With IV 0.9 percent NaCl.

Intravenous Preparation:

• Use aseptic methods and techniques while preparing anti-cancer medications.

• Use sterile water for injection (SWI) to slowly inject the vial to reconstitute it.

• Shake the container gently until all of the contents dissolve; do not shake.

• Check the reconstituted solution for particles and discoloration (from colorless to pale brown); if one of these conditions exists, do not use the solution.

• 100 mg vial and 5 mL of SWI to reconstitute.

• 160 mg vial and 8 mL of SWI were used to reconstitute.

• The concentration, as a result, is 20 mg/mL.

Diluting

• Transfer the calculated amount from the vial to a 250-mL infusion bag containing 0.9 % NaCl.

• To prevent foaming, gently invert the bag to combine the solution IV administration.

IV Administration:

• Use a 0.22 micron in-line nonprotein adsorptive polyethersulfone (PES) filter for IV infusion exclusively.

• Give NOT as a bolus or IV push.

• Avoid combining or infusing with other medications.

• Avoid using Trastuzumab in place of or in addition to ado-trastuzumab emtansine.

• Keep a close eye out for potential subcutaneous penetration at the IV infusion site.

• First Infusion: Give the medication over 90 minutes, and monitor the patient for at least 90 minutes following the infusion to look for fever, chills, or other infusion-related reactions (IRRs).

• Recurring Infusions: If the initial infusion was well tolerated, give it over 30 minutes; monitor for IRRs both during and for at least 30 minutes following the infusion.

• If an IRR occurs, reduce or stop the dosage; if there are responses that could be fatal, stop taking it altogether.

• Give the dose as soon as possible if it is missing or postponed.

Conclusion:

Tratuzumab-related liver damage has always been self-limited and unrelated to symptoms or jaundice. Regarding potential cross-sensitivity to the harm between various monoclonal antibodies or treatments targeting epidermal growth factor receptors, there is no evidence available. Trastuzumab has occasionally been tolerated at reduced dosages upon recovery, with just slight increases in alanine transaminase (ALT). On the other hand, ado-Trastuzumab emtansine is linked to a liver injury that is frequently severe and sometimes deadly. The monoclonal-cytotoxic conjugate causes chronic liver damage that is typically lasting, even though when the medication is stopped, the signs and symptoms normally go away. The medication should be stopped in patients who show signs of portal hypertension or nodular regeneration while on ado-Trastuzumab emtansine therapy.